A pre-planned substudy of a larger multicenter randomized trial was undertaken to compare the efficacy of everolimus with reduced-dose cyclosporine in the prevention of cardiac allograft vasculopathy ( CAV ) after heart transplantation to that of mycophenolate mofetil ( MMF ) with standard-dose cyclosporine .